In a study by Popat et al., ever-smokers with advanced NSCLC and PD-L1 TPS ≥ 50% who initiated first-line pembrolizumab exhibited significantly prolonged OS compared to never-smokers [14]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.